Mobile

A Phase 2, Randomized, Double Blind, Placebo- Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy- Induced Thrombocytopenia in Subje...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003699-36

A Phase 2, Randomized, Double Blind, Placebo- Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy- Induced Thrombocytopenia in Subjects With Advanced Non- Small Cell Lung Cancer Already Receiving Gemcitabine and Platinum

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety of AMG 531 in treating CIT in NSCLC subjects receiving myelosuppressive chemotherapy.

Critère d'inclusion

  • Secondary prophylaxis for the treatment of chemotherapy induced thrombocytopenia (CIT) in subjects with Non-Small Cell Lung Cancer (NSCLC) receiving myelosuppressive chemotherapy

Liens